| Date Filed | Type | Description |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/06/2020 |
SC 13D/A
| ARCH VENTURE FUND VI LP reports a 5.7% stake in VBI Vaccines, Inc. |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/23/2019 |
4
| GILLIS STEVEN (Director) has filed a Form 4 on VBI VACCINES INC.|
Txns:
| Bought 10,000,000 shares
@ $0.5, valued at
$5M
|
|
| 09/05/2019 |
GN
| VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference |
| 07/01/2019 |
GN
| VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes |
| 06/20/2019 |
GN
| VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference |
| 06/17/2019 |
GN
| VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac® |
| 06/16/2019 |
GN
| VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac® |
| 06/13/2019 |
GN
| VBI Vaccines Announces Results of Annual General Meeting |
| 05/01/2019 |
GN
| VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update |
| 04/19/2019 |
GN
| New Research Coverage Highlights Turquoise Hill Resources, GDS HOLDINGS, AptarGroup, VBI Vaccines, Loral Space and Communications, and FEDNAT HOLDING CO — Consolidated Revenues, Company Growth, and Expectations for 2019 |
| 04/17/2019 |
GN
| VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs |
| 04/11/2019 |
GN
| VBI Vaccines Appoints Joanne Cordeiro to Board of Directors |
| 04/09/2019 |
GN
| VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019 |
| 02/11/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/16/2019 |
GN
| VBI Vaccines Appoints Blaine McKee to Board of Directors |
| 12/20/2018 |
GN
| VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate |
| 12/18/2018 |
GN
| VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter's Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million |
| 12/13/2018 |
GN
| VBI Vaccines Announces Pricing of $37.5 Million Public Offering |
| 12/12/2018 |
GN
| VBI Vaccines Announces Proposed Public Offering of Common Shares |
| 11/09/2018 |
GN
| VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update |
| 09/26/2018 |
GN
| VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards |
| 09/16/2018 |
GN
| VBI Vaccines Responds to Unfounded Allegations in Globes Article |
| 08/28/2018 |
GN
| VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference |
| 05/29/2018 |
SC 13G
| MENORA MIVTACHIM HOLDINGS LTD. reports a 5.4% stake in VBI Vaccines, Inc. |
| 02/09/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/19/2017 |
4
| Baxter Jeff (CEO, President) has filed a Form 4 on VBI VACCINES INC. |
| 04/19/2017 |
3
| Baxter Jeff (President and CEO) has filed a Form 3 on VBI VACCINES INC. |
| 04/19/2017 |
4
| DeWilde Michel (Director) has filed a Form 4 on VBI VACCINES INC.|
Txns:
| Granted 12,500 options to buy
@ $3.79, valued at
$47.4k
|
|
| 04/19/2017 |
3
| DeWilde Michel (Director) has filed a Form 3 on VBI VACCINES INC. |
| 03/31/2017 |
SC 13D
| Opko Health, Inc. reports a 15% stake in VBI Vaccines, Inc. |
| 03/09/2017 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 21.5% stake in VBI VACCINES INC. |
| 03/09/2017 |
4/A
| PERCEPTIVE ADVISORS LLC (10% Owner) has filed a Form 4 on VBI VACCINES INC. |
|